SavedAdd your journal

Journals / Turkish Journal of Medical Sciences / 2013 / Cilt: 43 - Sayı: 1

MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels in epidermoid lung cancer

AKÖZ Mehmet
Burhan APİLİOĞULLARI
Murat ÖNCEL
Aysel KIYICI
Müfide ÖNCEL
Pages
104–109
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:To investigate serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 complex in epidermoid lung cancer and determine whether one of these markers or any combination of them can be used as a prognostic factor and in the management of this disease.
📊
Key Findings & Data:Materials and methods: Twenty-eight patients with non-small cell lung cancer and 21 healthy, age-matched individuals participated in this study.
💡
Conclusion & Impact:However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Key words: Epidermoid lung cancer · MMP-2 · TIMP-2

Abstract

To investigate serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 complex in epidermoid lung cancer and determine whether one of these markers or any combination of them can be used as a prognostic factor and in the management of this disease. Materials and methods: Twenty-eight patients with non-small cell lung cancer and 21 healthy, age-matched individuals participated in this study. MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were measured in the sera of the patients and controls with the ELISA technique. Results: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were significantly elevated in patients with non-small cell lung cancer compared to the controls (P = 0.018, 0.041, and 0.034, respectively). Conclusion: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels increased not only in lung tissues, but in the sera of the patients with non-small cell lung cancer. However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.

Özet

To investigate serum levels of MMP-2, TIMP-2, and MMP-2/TIMP-2 complex in epidermoid lung cancer and determine whether one of these markers or any combination of them can be used as a prognostic factor and in the management of this disease. Materials and methods: Twenty-eight patients with non-small cell lung cancer and 21 healthy, age-matched individuals participated in this study. MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were measured in the sera of the patients and controls with the ELISA technique. Results: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels were significantly elevated in patients with non-small cell lung cancer compared to the controls (P = 0.018, 0.041, and 0.034, respectively). Conclusion: MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels increased not only in lung tissues, but in the sera of the patients with non-small cell lung cancer. However, further studies are needed to fully evaluate the expression rates and diagnostic efficiency of these parameters in different histopathological subtypes of this cancer and in prospective research with a large number of participants.

🔖

Cite This Article

Mehmet, A., APİLİOĞULLARI, B., ÖNCEL, M., KIYICI, A., ÖNCEL, M. (2022). MMP-2, TIMP-2, and MMP-2/TIMP-2 complex levels in epidermoid lung cancer. Turkish Journal of Medical Sciences, Cilt: 43 - Sayı: 1, 104–109. https://ajindex.com/articles/611072

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Kırgıl G, Deveci F, Turgut T, Muz HM, Kaçar C. Akciğer kanserinin epidemiyolojik özelliklerinin retrospektif olarak karşılaştırmalı değerlendirilmesi. F.Ü. Sağlık Bilimleri Dergisi 2005; 19: 165–9.
  2. Shih JY, Tsai MF, Chang TH, Chang YL, Yuan A, Yu CJ et al. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin Cancer Res 2005; 11: 8070–8078.
  3. Apakkan AS, Bayındır O, Özmen D. Metalloproteinazlar, inhibitörleri ve ilişkili fizyolojik ve patolojik durumlar. Turk Klin Tıp Bilim 2001; 21: 332–42.
  4. Hewitt R, Dan K. Stromal cell expression of components of matrix degrading protease systems in human cancer. Enzyme Protein 1996; 49: 163–73. Matrisian LM. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990; 6: 121–5.
  5. Sethi CS, Bailey TA, Luthert PJ, Chong NHV. Matrix metalloproteinase biology applied to vitreoretinal disorders. Br J Ophthalmol 2000; 84: 654–64.
  6. Oğuz SH, Çamlıca H, Duranyılmaz D, Kaytan Sağlam E, Taş F, Yasasever V et al. Matriks metalloproteinazlar ve akciğer kanseri. Turk Onkol Der 2006; 21: 53–6.
  7. Laack E, Kohler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G et al. Pretreatment serum levels of matrix metalloproteinase–9 and vascular endothelial growth factor in non-small cell lung cancer. Ann Oncol 2002; 13: 1550–7.
  8. Yang SF, Hsieh YS, Lin CL, Hsu NY, Chiou HL, Chou FP et al. Increased plasma levels of urokinase plasminogen activator and matrix metalloproteinase–9 in non-small cell lung cancer patients. Clin Chim Acta 2005; 354: 91–9.
  9. Güllü IH, Kurdoğlu M, Akalin I. The relation of gelatinase (MMP-2 and -9) expression with distant site metastasis and tumour aggressiveness in colorectal cancer. British Journal of Cancer 2000; 82: 246–249.
  10. Akalin İ, Güllü İH, Kurdoğlu M, Marangoz S. Why hepatocellular carcinoma cells are unlikely to metastasize: is there a role for tissue inhibitor of metalloproteinase-1? Med Hypotheses 2001; 57: 221–3.
  11. Kurdoğlu M, Güllü İH, Akalin İ. Is there a relationship between tissue inhibitor of metalloproteinase-1 and transforming growth factor-beta 1 with respect to malignant melanoma progression? Med Hypotheses 2001; 57: 238–40.
  12. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999; 274: 21491–4.
  13. Lambert E, Dassé E, Haye B, Petitfrère E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004; 49: 187–98.
  14. Chia MM, Gazdar AF, Carbone DP, Minna JD. Neoplasms of the lungs. In: Murray JF, Nadel JA, editors. Textbook